- Home
- HUT vs TVTX Comparison
HUT vs TVTX Comparison
Compare HUT & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUT
- TVTX
- Stock Information
- Founded
- HUT 2011
- TVTX 2008
- Country
- HUT United States
- TVTX United States
- Employees
- HUT N/A
- TVTX N/A
- Industry
- HUT Finance: Consumer Services
- TVTX Biotechnology: Pharmaceutical Preparations
- Sector
- HUT Finance
- TVTX Health Care
- Exchange
- HUT Nasdaq
- TVTX Nasdaq
- Market Cap
- HUT 1.8B
- TVTX 1.8B
- IPO Year
- HUT N/A
- TVTX N/A
- Fundamental
- Price
- HUT $17.93
- TVTX $21.98
- Analyst Decision
- HUT Strong Buy
- TVTX Strong Buy
- Analyst Count
- HUT 8
- TVTX 12
- Target Price
- HUT $35.25
- TVTX $30.08
- AVG Volume (30 Days)
- HUT 4.3M
- TVTX 1.9M
- Earning Date
- HUT 03-03-2025
- TVTX 02-20-2025
- Dividend Yield
- HUT N/A
- TVTX N/A
- EPS Growth
- HUT N/A
- TVTX N/A
- EPS
- HUT 1.91
- TVTX N/A
- Revenue
- HUT $194,021,000.00
- TVTX $233,175,000.00
- Revenue This Year
- HUT $41.71
- TVTX $62.88
- Revenue Next Year
- HUT $65.24
- TVTX $57.60
- P/E Ratio
- HUT $8.92
- TVTX N/A
- Revenue Growth
- HUT 209.07
- TVTX 60.55
- 52 Week Low
- HUT $6.77
- TVTX $5.12
- 52 Week High
- HUT $31.95
- TVTX $25.29
- Technical
- Relative Strength Index (RSI)
- HUT 31.22
- TVTX 53.52
- Support Level
- HUT $19.52
- TVTX $22.48
- Resistance Level
- HUT $20.54
- TVTX $23.69
- Average True Range (ATR)
- HUT 1.34
- TVTX 1.22
- MACD
- HUT -0.16
- TVTX -0.02
- Stochastic Oscillator
- HUT 2.77
- TVTX 41.10
About HUT Hut 8 Corp.
Hut 8 Corp is engaged in the mining of digital assets with an operational focus on utilizing specialized equipment to solve complex computational problems to validate transactions on the Bitcoin blockchain and receiving Bitcoin in return for successful services. The company has four reportable business segments: Digital Assets Mining, Managed Services, High Performance Computing -Colocation and Cloud, and Other. It derives maximum revenue from Digital Assets Mining segment.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.